News and Press Releases
Psyence Group Announces SEC Effectiveness Of F-4 For Proposed Business Combination Between Subsidiary And NASDAQ Listed Newcourt Acquisitions Corp
Psyence Group Inc. (CSE:PSYG), a clinical-stage life science biotechnology company pioneering the use of nature-derived psilocybin in mental health and wellbeing (“Psyence”), and Newcourt Acquisition Corp (Nasdaq: NCAC) (“Newcourt”), a special purpose acquisition company today announced that the registration statement on Form F-4 (the “Registration Statement”), filed by Psyence Biomedical Ltd. (“Pubco”) with the Securities and Exchange Commission (“SEC”) was declared effective by the SEC on November 13, 2023.
Psyence Production Expands Capability
Psyence recently designed a new laboratory at the facility in order to expand its extraction capabilities. The building of the laboratory has since commenced and is expected to be completed in Q4 2023. The expansion fits under the existing building footprint, and once completed, new state-of-the-art extraction equipment will be installed to enhance its current extraction capabilities. There are multiple potential benefits to on-site extraction including increased product shelf life, a more stabilized format for export, and reduced transport costs.
Psyence Group Announces Closing Of Private Placement & Conclusion Of Loan Agreement
Psyence announces that it has issued 1,056,441 common shares at a price of CAD$0.12 per common share for gross proceeds of CAD$126,773.
Psyence Group Announces SEC Registration Filing with NASDAQ SPAC, Newcourt, and Signing of Amended and Restated Business Combination Agreement
Psyence Group Announces SEC Registration Filing with NASDAQ SPAC, Newcourt, and Signing of Amended and Restated Business Combination Agreement
Psyence Group Corporate Update
Since Psyence’s corporate update issued in June 2022, the Company has made significant progress in its clinical trial programs and in upgrading its production facility and extraction capabilities. Psyence is executing on its strategy and is pleased to provide an update across the pillars of the business.
Psyence Appoints Intellectual Property Expert To Its Board Of Directors
Psyence is pleased to announce the appointment of Christopher Bull to the board of directors of the Company effective immediately.
Psyence Group Announces Closing Of Previously Announced Financing
Psyence announces that it has issued 7,775,964 common shares at a price of CAD$0.12 per common share and 3,887,982 warrants for aggregate proceeds of CAD$ 933,116 to Cantheon Capital LLC.
Psyence Group Announces Closing Of Fourth Round Tranche Of Private Placement And Conversion Of Convertible Debt Note
Psyence is pleased to announce that it has issued 9,043,038 common shares at a price of CAD$0.12 per common share for gross proceeds of CAD$1,085,164. This brings the total amount the Company has raised pursuant to the previously announced private placement to CAD $3.04 million ("Aggregate Proceeds").
Psyence Group Announces Cantheon Capital Private Placement
Psyence is pleased to announce that it has entered into a brokered subscription agreement with Cantheon Capital, LLC (“Cantheon”). Cantheon, a fund focussed on listed biotech stocks with near term catalysts,
